Sökning: onr:"swepub:oai:DiVA.org:kau-2218" > The Prostaglandin E...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05170naa a2200625 4500 | |
001 | oai:DiVA.org:kau-2218 | |
003 | SwePub | |
008 | 111016s2004 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:kau-24700 | |
009 | oai:DiVA.org:liu-22156 | |
009 | oai:DiVA.org:kau-3195 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-22182 URI |
024 | 7 | a https://doi.org/10.1111/j.0022-202X.2004.22339.x2 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-247002 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-221562 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-31952 URI |
040 | a (SwePub)kaud (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Mørk, Catou Department of Dermatology, Rikshospitalet University Hospital, Norway4 aut |
245 | 1 0 | a The Prostaglandin E1 Analog Misoprostol Reduces Symptoms and Microvascular Arteriovenous Shunting in Erythromelalgia :b A Double-Blind, Crossover, Placebo-Compared Study |
264 | 1 | b Nature Publishing Group,c 2004 |
338 | a electronic2 rdacarrier | |
520 | a Based on previous experience with parenteral prostanoids, we studied the effect of misoprostol treatment, an orally administered prostaglandin E1 analog, in patients with erythromelalgia. Treatment with placebo was followed by treatment with misoprostol (0.4–0.8 mg per d), both for 6 wk. The patients (n=21) and a study nurse who administered the trial were blinded. The endpoints were change in pain and need for cooling and global assessment of the treatment. Following central body heat provocation, global skin perfusion, capillary morphology, and change in pain were also recorded before and after each treatment period. Results were compared with data from healthy control subjects (n=11) that did not undergo treatment. Clinical safety and tolerability evaluation included physical examinations, clinical laboratory tests, and monitoring of adverse events. All clinical outcome measures were significantly better after treatment with misoprostol (p<0.01) as compared with placebo treatment and after a 3-mo follow-up without treatment. The heat-induced increase in global perfusion after misoprostol treatment was similar to the control group and significantly lower when compared with baseline (p<0.01) and placebo treatment (p<0.05), respectively. This study demonstrates that misoprostol is clinically superior to placebo in patients with erythromelalgia. The results of the perfusion studies may imply that the mechanism of action of the beneficial effect of misoprostol is reduced microvascular arteriovenous shunting in affected skin. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Dermatologi och venereologi0 (SwePub)302042 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Dermatology and Venereal Diseases0 (SwePub)302042 hsv//eng |
650 | 7 | a NATURVETENSKAPx Data- och informationsvetenskapx Datorseende och robotik0 (SwePub)102072 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Computer and Information Sciencesx Computer Vision and Robotics0 (SwePub)102072 hsv//eng |
653 | a arteriovenous shunting | |
653 | a clinical trial | |
653 | a microcirculation | |
653 | a prostanoids | |
653 | a Dermatology and venerology | |
653 | a Dermatologi och venerologi | |
653 | a MEDICINE | |
653 | a Image analysis | |
653 | a Biomedicinsk lab. Vetenskap | |
700 | 1 | a Salerud, Göran,d 1954-u Linköpings universitet,Tekniska högskolan,Biomedicinsk instrumentteknik,Department of Biomedical Engineering, Linköping University4 aut0 (Swepub:liu)gorsa75 |
700 | 1 | a Asker, Claes L,d 1966-u Karlstads universitet,Institutionen för kemi4 aut0 (Swepub:kau)claeaske |
700 | 1 | a Kvernebo, Knutu Department of Cardiothoracic Surgery, Ullevaal University Hospital, Norway4 aut |
710 | 2 | a Department of Dermatology, Rikshospitalet University Hospital, Norwayb Tekniska högskolan4 org |
773 | 0 | t Journal of Investigative Dermatologyd : Nature Publishing Groupg 122:3, s. 587-593q 122:3<587-593x 0022-202Xx 1523-1747 |
773 | 0 | t Journal of Investigative Dermatology Volume 122, Issue 3, Page 587-593, Mar 2004d : Nature Publishing Groupg 122:3, s. 587-593q 122:3<587-593 |
856 | 4 | u https://kau.diva-portal.org/smash/get/diva2:24558/FULLTEXT01.pdfx primaryx Raw objecty fulltext:preprint |
856 | 4 | u http://dx.doi.org/10.1111/j.0022-202X.2004.22339.x |
856 | 4 | u http://kau.diva-portal.org/smash/get/diva2:128368/FULLTEXT01 |
856 | 4 | u http://www.nature.com/jid/journal/v122/n3/full/5602219a.html |
856 | 4 | u https://kau.diva-portal.org/smash/get/diva2:128368/FULLTEXT01.pdfx primaryx Raw objecty fulltext:postprint |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-2218 |
856 | 4 8 | u https://doi.org/10.1111/j.0022-202X.2004.22339.x |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-24700 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-22156 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-3195 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.